ARV-6723 is an investigational, oral PROTAC designed to degrade hematopoietic progenitor kinase 1 (HPK1) in adults with advanced solid tumors, marking Arvinas as the first company to bring an HPK1 PROTAC degrader into clinical trials in the United States.